Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma

BACKGROUND: The combination of JAK/STAT and HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. We aim to investigate the efficacy of JAK1/2i ruxolitinib in combination with HDACi resminostat in CTCL in vitro. MATERIAL & METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagianni, Fani, Piperi, Christina, Mpakou, Vassiliki, Spathis, Aris, Foukas, Periklis G., Dalamaga, Maria, Pappa, Vasiliki, Papadavid, Evangelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951910/
https://www.ncbi.nlm.nih.gov/pubmed/33705488
http://dx.doi.org/10.1371/journal.pone.0248298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951910/
https://www.ncbi.nlm.nih.gov/pubmed/33705488
http://dx.doi.org/10.1371/journal.pone.0248298

Ejemplares similares